ACE and Abnormal renal physiology: The addition ofolmesartan to patients treated by the combination of ACE inhibitors and betablockers was, however, associated with a significant increase in the occurrenceof the primary endpoint (HR = 1.47; 95% CI, 1.11-1.95; p = 0.006) all-causedeath and renal dysfunction.